1Department of Infectious Diseases, University Hospital Bern, Freiburgstrasse, 3010 Bern, Switzerland.
2Paediatric Pharmacology and Pharmacometrics, University of Basel Children's Hospital, Basel, Switzerland.
Antimicrob Resist Infect Control. 2019 Jan 29;8:21. doi: 10.1186/s13756-019-0474-x. eCollection 2019.
Catheter-related bloodstream infections (CRBSI) with coagulase-negative Staphylococci (CoNS) are a common source of hospital-acquired bloodstream infections. The main objective of this study was to elucidate the role of systemic antibiotic therapy in the setting of catheter removal in adult patients with CoNS-CRBSI.
We conducted a retrospective cohort study on patients with CoNS-CRBSI diagnosed between 2008 and 2016 with follow-up for up to 12 months. The main inclusion criterion was a removed intravascular catheter with quantitative catheter tip culture growing CoNS and the same CoNS identified in the blood culture of a given patient. Outcomes were (i.e. either presence of prolonged bacteremia or symptoms attributed to CoNS-CRBSI > 2 days after catheter removal), , and after catheter removal. We compared outcomes between a group with antibiotic treatment prescribed according to current IDSA guidelines (≥5 days, "treatment" group) and a "no-treatment" group.
Our study population comprised 184 CoNS-CRBSI episodes. Seventy-six percent received antibiotic treatment ≥5 days, while 17% did not receive therapy. were absent from the patients who did not receive antibiotics. Severe neutropenia, hematologic cancer and immunosuppression were significantly more frequent in the treatment group. The subgroup analysis with 32 matched pairs showed no significant difference in frequency of non-resolved infection (0% in the no-treatment vs 15.6% in the ≥5 days treatment group, = 0.06). The remaining outcomes were similar in the two groups.
Our findings indicate that withholding antimicrobial therapy in CoNS-CRBSI is neither associated with short-term complications nor with long-term recurrences.
凝固酶阴性葡萄球菌(CoNS)引起的导管相关血流感染(CRBSI)是医院获得性血流感染的常见来源。本研究的主要目的是阐明在移除导管的情况下,全身抗生素治疗在 CoNS-CRBSI 成年患者中的作用。
我们对 2008 年至 2016 年间诊断为 CoNS-CRBSI 的患者进行了回顾性队列研究,随访时间长达 12 个月。主要纳入标准为定量导管尖端培养生长 CoNS 的血管内导管已移除,且同一 CoNS 在特定患者的血培养中被识别。研究终点为导管移除后 2 天内是否存在持续性菌血症或归因于 CoNS-CRBSI 的症状(即治疗组,接受至少 5 天的抗生素治疗)和无治疗组。
我们的研究人群包括 184 例 CoNS-CRBSI 发作。76%的患者接受了至少 5 天的抗生素治疗,而 17%的患者未接受治疗。未接受抗生素治疗的患者中,未发生持续性菌血症或归因于 CoNS-CRBSI 的症状。严重中性粒细胞减少症、血液系统恶性肿瘤和免疫抑制在治疗组中更为常见。在 32 对匹配的亚组分析中,未接受治疗组的感染未缓解率(0%)与治疗组(≥5 天)(15.6%)无显著差异(=0.06)。两组的其余结局相似。
我们的研究结果表明,在 CoNS-CRBSI 中不使用抗菌治疗既不会导致短期并发症,也不会导致长期复发。